Literature DB >> 16709957

Rosiglitazone cools down inflammation in the metabolic syndrome.

Katherine Esposito, Miryam Ciotola, Domenico Merante, Dario Giugliano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16709957     DOI： 10.1161/01.ATV.0000223874.94624.11

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  7 in total

1.  Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease.

Authors:  James L Searcy; Jeremiah T Phelps; Tristano Pancani; Inga Kadish; Jelena Popovic; Katie L Anderson; Tina L Beckett; Michael P Murphy; Kuey-Chu Chen; Eric M Blalock; Philip W Landfield; Nada M Porter; Olivier Thibault
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  PPARs and nonalcoholic fatty liver disease.

Authors:  Kim H H Liss; Brian N Finck
Journal:  Biochimie       Date:  2016-12-02       Impact factor: 4.079

3.  The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels.

Authors:  Amanda L McGuire; Nadia Urosevic; Doris T Chan; Gursharan Dogra; Timothy J J Inglis; Aron Chakera
Journal:  PPAR Res       Date:  2014-10-13       Impact factor: 4.964

4.  Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease.

Authors:  Carmen M Fernandez-Martos; Rachel A K Atkinson; Meng I Chuah; Anna E King; James C Vickers
Journal:  Alzheimers Dement (N Y)       Date:  2016-12-20

Review 5.  Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.

Authors:  Takashi Kobayashi; Michihiro Iwaki; Atsushi Nakajima; Asako Nogami; Masato Yoneda
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208

6.  Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue.

Authors:  Ivana Zagotta; Elitsa Y Dimova; Jan-Bernd Funcke; Martin Wabitsch; Thomas Kietzmann; Pamela Fischer-Posovszky
Journal:  Oxid Med Cell Longev       Date:  2013-06-02       Impact factor: 6.543

Review 7.  Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.

Authors:  Brian N Finck
Journal:  Diabetes       Date:  2018-12       Impact factor: 9.461
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.